Med. praxi. 2011;8(12):532-536

Current trends in the treatment of pain

MUDr.Marek Hakl, Ph.D., MUDr.Boris Leštianský
ARK, Centrum pro léčbu bolesti LF MU a FN u sv. Anny v Brně

In the last year we were in the area of pain management met with a number of innovations. They were published new recommended

practices for the treatment of neuropathic pain EFNS, there were new active substances and new formulations. The news for systemic

administration are mainly new transmucosal fentanyl for the treatment of breakthrough pain in cancer patients and a new active substance

tapentadol, which should appear first retarded form and subsequently in the form of a quick release. Is enriched by a group of

steroid anti-inflammatory drugs lornoxicam a new molecule. Interesting news appeared in the local treatment of neuropathic pain,

postherpetic pain for the treatment is intended to patch 5% and lidocaine for the treatment of mononeuropathies patch for a single

injection with 8% capsaicin.

Keywords: neuropathic pain, breakthrough pain, fentanyl transmucosal, tapentadol, lornoxicam

Published: December 15, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hakl M, Leštianský B. Current trends in the treatment of pain. Med. praxi. 2011;8(12):532-536.
Download citation

References

  1. Doležal T, Hakl M, Kozák J, Kršiak M, Lejčko J, Skála B, Sláma O, Ševčík P, Vorlíček J: Metodické pokyny pro farmakoterapii bolesti. Bolest 2009; 12(Suppl 2): 24-27.
  2. World Health Organisation. Cancer Pain Relief: with a guide to opioid availability. WHO press 1986.
  3. Attal N, Cruccu G, Baron R, Haanpaa M, Hanson P, Jensen T, Numikko T: EFNS guidelines on the pharmacological treatment of neuropathic pain: 2009 revision. European Journal of Neurology 2009; 8: 1010-1018. Go to original source... Go to PubMed...
  4. Katz J, Finnerup B, Dworkin RH. Clinical outcome in neuropathic pain: relationship to study characteristics. Neurology 2008; 28: 263-272. (class 1 SR). Go to original source... Go to PubMed...
  5. Davis A. Cancer related breakthrough pain. Oxford University Press 2006: 1-11. Go to original source...
  6. Christrup LL, Foster D, Popper L. Pharmacokinetics, efficiency and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction. Clin Ther 2008; 30: 469-481. Go to original source... Go to PubMed...
  7. Kabelka L, Kozák J, Lejčko J, Sláma O. Doporučený postup pro léčbu průlomové bolesti. Bolest 2011; 14(Suppl 1).
  8. Barclay L, Bernard M. Venlafaxine Helpful in Painful Polyneuropathy. Neurology 2003; 60: 1284-1289. Go to original source... Go to PubMed...
  9. Yakhno N, Guekht A, Skoromets A, et al. Analgesic efficacy and safety of lornoxicam quick-release formulation compared with diclofenac potassium: randomised, double-blind trial in acute low back pain. Clin Drug Investig 2006; 26: 267-77. Go to original source... Go to PubMed...
  10. Kidd B, Frenzel W. A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. J Rheumatol 1996; 23: 1605-1611. Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.